Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Derazantinib in advanced intrahepatic cholangiocarcinoma
NCT03230318Phase 2Completed
- Sponsor
- Basilea Pharmaceutica
- Start
- Sep 2017
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 11
01
Overview
A Phase 2 trial of derazantinib in intrahepatic cholangiocarcinoma (ICC), sponsored by Basilea Pharmaceutica. Started Sep 2017; status: completed.
02
Drugs
derazantinib
03
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on NCT03230318.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03230318.